C-phycocyanin, a very potent and novel platelet aggregation inhibitor from Spirulina platensis

Journal of Agricultural and Food Chemistry

Volumn 53, Issue 20, 2005, Pages 7734-7740

  Hsiao, George ^a   Chou, P O Hiu ^a   Shen, Ming Yi ^a   Chou, Duen Suey ^a   Lin, Chien Huang ^a   Sheu, Joen Rong ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Blue green alga; C phycocyanin; Cyclic GMP; Hydroxyl radical; Protein kinase C; Thromboxane A2; Vasodilator stimulated phosphoprotein

Indexed keywords

ANTITHROMBOCYTIC AGENT; BACTERIAL PROTEIN; CALCIUM; COLLAGEN; FIBRINOGEN RECEPTOR; PHOSPHATIDYLINOSITOL; PHYCOCYANIN;

ARTICLE; BLOOD; CHEMISTRY; DRUG EFFECT; HUMAN; PHOSPHORYLATION; PROTEIN CONFORMATION; SPIRULINA; THROMBOCYTE; THROMBOCYTE AGGREGATION;

BACTERIAL PROTEINS; BLOOD PLATELETS; CALCIUM; COLLAGEN; HUMANS; PHOSPHATIDYLINOSITOLS; PHOSPHORYLATION; PHYCOCYANIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN CONFORMATION; SPIRULINA;

CYANOBACTERIA; SPIRULINA PLATENSIS;

EID: 27144513771     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf051352y     Document Type: Article

References (32)

1. Sarada, R.; Manoj, G.; Pillai, M. G.; Ravishankar, G. A. Phycocyanin from Spirulina sp: Influence of processing of biomass on phycocyanin yield, analysis of efficacy of extraction methods and stability studies on phycocyanin. Proc. Biochem. 1999, 34, 795-801.
2. Henrikson, R. In Earth food Spirulina; Henrikson, R., Ed.; Ronore Enterprises: Laguna Beach, CA, 1989.
3. Vadiraja, B. B.; Gaikwad, N. W.; Madyastha, K. M. Hepato-protective effect of C-phycocyanin: Protection for carbon tetrachloride and R-(+)-pulegone mediated hepatotoxicity in rats. Biochem. Biophys. Res. Commun. 1998, 249, 428-431.
4. Romay, C.; Armesto, J.; Remirez, D.; Gonzalez, R.; Ledon, N.; Garcis, I. Antioxidant and antiinflammatory properties of C-phycocyanin from blue green algae. Inflamm. Res. 1998, 47, 36-41.
5. Bhat, V. B.; Madyastha, K. M. C-phyocyanin: A potent peroxyl radical scavenger in vitro and in vivo. Biochem. Biophys. Res. Commun. 2000, 275, 20-25.
6. Folts, J. D. Potential health benefits from the flavonoids in grape products on vascular disease. Adv. Exp. Med. Biol. 2002, 505, 95-111.
7. Remirez, D.; Gonzalez, A.; Merino, N.; Gonzalez, R.; Ancheta, O.; Romay, C.; Rodriguez, S. Effect of phycocyanin in zymosan-induced arthritis in mice-phycocyanin as an antiarthritic compound. Drug Dev. Res. 1999, 48, 70-75.
8. Kronik, M.; Grossman, P. Immunoassay techniques with fluorescent phycobiliprotein conjugates. Clin. Chem. 1983, 29, 1582-1586.
9. Sheu, J. R.; Chao, S. H.; Yen, M. H.; Huang, T. F. In vivo antithrombotic effect of triflavin, an Arg-Gly-Asp containing peptide on platelet plug formation in mesenteric microvessels of mice. Thromb. Haemost. 1994, 72, 617-621.
10. Schleinitz, M. D.; Weiss, J. P.; Owens, D. K. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: A cost-effectiveness analysis. Am. J. Med. 2004, 116, 797-806.
11. Sheu, J. R.; Lee, C. R.; Lin, C. C.; Kan, Y. C.; Lin, C. H.; Hung, W. C.; Yen, M. H. The antiplatelet activity of PMC, a potent α-tocopherol analogue, is mediated through inhibition of cyclooxygenase. Br. J. Pharmacol. 1999, 127, 1206-1212.
12. Sheu, J. R.; Hung, W. C.; Wu, C. H.; Ma, M. C.; Kan, Y. C.; Lin, C. H.; Lin, M. S.; LUK, H. N.; YEN, M. H. Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia. Circulation 1999, 99, 3056-3062.
13. Sheu, J. R.; Lin, C. H.; Peng, C. H.; Huang, T. F. Triflavin, an Arg-Gly-Asp-containing peptide, inhibits the adhesion of tumor cells to matrix protein via binding to multiple integrin receptors expressed on human hepatoma cells. Proc. Soc. Exp. Biol. Med. 1996, 213, 71-79.
14. 2+ indicator with greatly improved fluorescence properties. J. Biol. Chem. 1985, 260, 3440-3450.
15. Sheu, J. R.; Fong, T. H.; Liu, C. M.; Shen, M. Y.; Chen, T. L.; Chang, Y.; Lu, M. S.; Hsiao, G. Expression of matrix metalloproteinase-9 in human platelets: Regulation of platelet activation in in vitro and in vivo studies. Br. J. Pharmacol. 2004, 143, 193-201.
16. Li, Z.; Ajdic, J.; Eigenthaler, M.; Du, X. A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans. Blood 2003, 101, 4423-4429.
17. Hsiao, G.; Shen, M. Y.; Lin, K. H.; Chou, C. Y.; Tzu, N. H.; Lin, C. H.; Chou, D. S.; Chen, T. F.; Sheu, J. R. Inhibitory activity of kinetin on free radical formation of activated platelets in vitro and on thrombus formation in vivo. Eur. J. Pharmacol. 2003, 465, 281-287.
18. Siess, W.; Lapetina, E. G. Platelet aggregation induced by alpha 2-adrenoceptor and protein kinase C activation. A novel synergism. Biochem. J. 1989, 263, 377-385.
19. Yoshioka, Y.; Yamamuro, A.; Maeda, S. Nitric oxide at a low concentration protects murine macrophage RAW264 cells against nitric oxide-induced death via cGMP signaling pathway. Br. J. Pharmacol. 2003, 139, 28-34.
20. Zhao, Y.; Brandish, P. E.; Divalentin, M.; Schelvis, J. P.; Babcock, G. T.; Marietta, M. A. 2000. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 2000, 39, 10848-10854.
21. 2/NaOH/DMSO system. J. Agric. Food Chem. 1999, 47, 2544-2548.
22. Fox, J. E. Transmembrane signaling across the platelet integrin glycoprotein IIb-IIIa. Ann. N. Y. Acad. Sci. 1994, 714, 75-87.
23. 2 production. Biochem. Pharmacol. 1982, 31, 1158-1160.
24. McKean, M. L.; Smith, J. B.; Silver, W. J. Formation of lysophosphatidylcholine in human platelets in response to thrombin. J. Biol. Chem. 1981, 256, 1522-1524.
25. 2+, phospholipid-dependent protein kinase associated with plasma membrane. Nature 1983, 301, 621-623.
26. Murohara, T.; Parkinson, S. J.; Waqldman, S. A.; Lefer, A. M. Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets. Role of protein kinase C. Arterioscler. Thromb. Vasc. Biol. 1995, 15, 2068-2075.
27. McDonald, L. J.; Murad, F. Nitric oxide and cyclic GMP signaling. Proc. Soc. Exp. Biol. Med. 1996, 211, 1-6.
28. Aszodi, A.; Pfeifer, A.; Ahmad, M.; Glauner, M.; Zhou, X. H.; Ny, L.; Andersson, K. E.; Kegrel, B.; Offermanns, S.; Fassler, R. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J. 1999, 18, 37-48.
29. Iuliano, L.; Colavita, A. R.; Leo, R.; Pratico, D.; Violi, F. Oxygen free radicals and platelet activation. Free Radic. Biol. Med. 1997, 22, 999-1006.
30. 2+ dependent mechanism. Arch. Biochem. Biophys. 1989, 270, 478-488.
31. 2 in human low-density lipoprotein. Biochim. Biophys. Acta 2002, 1583, 176-184.
32. Leo, R.; Ghisell, I. A.; Iuliano, L.; Violi, F. Detection of hydroxyl radicals by the salicylate bis-hydroxylation during arachidonic acid-dependent platelet activation. Thromb. Haemost. 1995, 73, A347.